Cost Analysis of Several Treatment Sequences Used for The Treatment of Relapsing-Remitting Multiple Sclerosis In Portugal: The Case for Cladribine Tablets

Abstract

0 1 7 ) A 3 9 9 -A 8 1 1 A721 physiotherapist. Finally, 6.2% of patients were hospitalized for MS (average duration of 3.6 days). Comparing MS patients to a matched control group resulted in estimating the excess direct cost attributable to MS to 9,659€ (±6,059€ ) in 2014 (average annual growth rate: 3.9% over [2012][2013][2014]. Main cost drivers were pharmaceuticals (49%), hospital care (22.9%), nursing care (7.8%), medical devices (6.5%) and physiotherapy care (6%). ConClusions: The direct burden of MS was evaluated to 965 € million in 2014 in France mainly due to disease-modifying therapies. Such burden highlights the importance of developing cost-effective drugs.